{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:46:36Z","timestamp":1791953196544,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"DOI":"10.1007\/s13555-026-01950-4","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:43:49Z","timestamp":1791927829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eczema\u2013Psoriasis Overlap: An eDelphi Consensus on Clinical Presentation and Therapeutic Management Among Italian Experts"],"prefix":"10.1007","author":[{"given":"Eleonora","family":"De Luca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-0839","authenticated-orcid":false,"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Caldarola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"1950_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","volume":"48","author":"E Guttman-Yassky","year":"2017","unstructured":"Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68\u201373. https:\/\/doi.org\/10.1016\/j.coi.2017.08.008.","journal-title":"Curr Opin Immunol"},{"key":"1950_CR2","doi-asserted-by":"publisher","first-page":"7527859","DOI":"10.1155\/2020\/7527859","volume":"2020","author":"A Bozek","year":"2020","unstructured":"Bozek A, Zajac M, Krupka M. Atopic dermatitis and psoriasis as overlapping syndromes. Mediat Inflamm. 2020;2020:7527859. https:\/\/doi.org\/10.1155\/2020\/7527859.","journal-title":"Mediat Inflamm"},{"key":"1950_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1541776","volume":"16","author":"M Li","year":"2025","unstructured":"Li M, Wang J, Liu Q, et al. Beyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis. Front Immunol. 2025;16:1541776. https:\/\/doi.org\/10.3389\/fimmu.2025.1541776.","journal-title":"Front Immunol"},{"issue":"6","key":"1950_CR4","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","volume":"123","author":"KE Nograles","year":"2009","unstructured":"Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing \u00abT22\u00bb T\u00a0cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T\u00a0cells. J Allergy Clin Immunol. 2009;123(6):1244-1252.e2. https:\/\/doi.org\/10.1016\/j.jaci.2009.03.041.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1950_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105518","volume":"23","author":"YC Tsai","year":"2022","unstructured":"Tsai YC, Tsai TF. Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes. Int J Mol Sci. 2022;23(10):5518. https:\/\/doi.org\/10.3390\/ijms23105518.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1950_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/JID.2015.378","volume":"136","author":"J Kim","year":"2016","unstructured":"Kim J, Oh CH, Jeon J, Baek Y, Ahn J, Kim DJ. Molecular phenotyping small (Asian) versus large (Western) plaque psoriasis shows common activation of IL-17 pathway genes but different regulatory gene sets. J Invest Dermatol. 2016;136(1):161\u201372.","journal-title":"J Invest Dermatol"},{"key":"1950_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15814","volume":"35","author":"G Paolino","year":"2022","unstructured":"Paolino G, Di Nicola MR, Brianti P, Bianchi VG, Mercuri SR. New onset atopic dermatitis and psoriasis in the same patients under biologic treatments: the role of systemic treatments as a possible trigger. Dermatol Ther. 2022;35:e15814. https:\/\/doi.org\/10.1111\/dth.15814.","journal-title":"Dermatol Ther"},{"issue":"7","key":"1950_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1080\/09546634.2019.1702147","volume":"32","author":"K Barry","year":"2021","unstructured":"Barry K, Zancanaro P, Casseres R, Abdat R, Dumont N, Rosmarin D. Concomitant atopic dermatitis and psoriasis\u2014a retrospective review. J Dermatol Treat. 2021;32(7):716\u201320. https:\/\/doi.org\/10.1080\/09546634.2019.1702147.","journal-title":"J Dermatol Treat"},{"issue":"8","key":"1950_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304651","volume":"19","author":"M Niederberger","year":"2024","unstructured":"Niederberger M, Schifano J, Deckert S, et al. Delphi studies in social and health sciences\u2014recommendations for an interdisciplinary standardized reporting (DELPHISTAR). Results of a Delphi study. PLoS ONE. 2024;19(8):e0304651. https:\/\/doi.org\/10.1371\/journal.pone.0304651.","journal-title":"PLoS ONE"},{"key":"1950_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07285-1","volume":"24","author":"J Webbe","year":"2023","unstructured":"Webbe J, Allin B, Knight M. How to reach agreement: the impact of different analytical approaches to Delphi process results in core outcomes set development. Trials. 2023;24:345. https:\/\/doi.org\/10.1186\/s13063-023-07285-1.","journal-title":"Trials"},{"issue":"4","key":"1950_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"IR Diamond","year":"2014","unstructured":"Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014;67(4):401\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.12.002.","journal-title":"J Clin Epidemiol"},{"key":"1950_CR12","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/jid.2011.376","volume":"132","author":"F Capon","year":"2012","unstructured":"Capon F, Burden AD, Trembath RC, Barker JN. Psoriasis and other complex trait dermatoses: from Loci to functional pathways. J Invest Dermatol. 2012;132:915\u201322. https:\/\/doi.org\/10.1038\/jid.2011.376.","journal-title":"J Invest Dermatol"},{"key":"1950_CR13","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139:1480\u20139. https:\/\/doi.org\/10.1016\/j.jid.2018.12.018.","journal-title":"J Invest Dermatol"},{"key":"1950_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2340\/00015555-2779","volume":"98","author":"M Kolesnik","year":"2018","unstructured":"Kolesnik M, Franke I, Lux A, Quist SR, Gollnick HP. Eczema in psoriatico: an important differential diagnosis between chronic allergic contact dermatitis and psoriasis in palmoplantar localization. Acta Derm Venereol. 2018;98:50\u20138. https:\/\/doi.org\/10.2340\/00015555-2779.","journal-title":"Acta Derm Venereol"},{"key":"1950_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/ddg.14991","volume":"21","author":"F Lauffer","year":"2023","unstructured":"Lauffer F, Eyerich K. Eczematized psoriasis\u2014a frequent but often neglected variant of plaque psoriasis. JDDG J Dtsch Dermatol Ges. 2023;21:445\u201353. https:\/\/doi.org\/10.1111\/ddg.14991.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"5","key":"1950_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1540-9740.2005.03636.x","volume":"4","author":"W Abramovits","year":"2005","unstructured":"Abramovits W, Cockerell C, Stevenson LC, Goldstein AM, Ehrig T, Menter A. PsEma\u2014a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema. Skinmed. 2005;4(5):275\u201381. https:\/\/doi.org\/10.1111\/j.1540-9740.2005.03636.x.","journal-title":"Skinmed"},{"issue":"1","key":"1950_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/all.15921","volume":"79","author":"S M\u00fcller","year":"2024","unstructured":"M\u00fcller S, Welchowski T, Schmid M, et al. Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the \u00abFlip-Flop\u00bb phenomenon). Allergy. 2024;79(1):164\u201373. https:\/\/doi.org\/10.1111\/all.15921.","journal-title":"Allergy"},{"key":"1950_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1056\/NEJMoa1106182","volume":"365","author":"S Eyerich","year":"2011","unstructured":"Eyerich S, Onken AT, Weidinger S, et al. Mutual antagonism of T\u00a0cells causing psoriasis and atopic eczema. N Engl J Med. 2011;365:231\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1106182.","journal-title":"N Engl J Med"},{"key":"1950_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.23736\/S2784-8671.24.07720-X","volume":"159","author":"F Bardazzi","year":"2024","unstructured":"Bardazzi F, Pileri A, Clarizio G, Pilipenko A, Loi C, Sacchelli L. Psoriasis dermatitis: a new entity or a different phenotypic expression of psoriasis and atopic dermatitis? Ital J Dermatol Venerol. 2024;159:166\u201373. https:\/\/doi.org\/10.23736\/S2784-8671.24.07720-X.","journal-title":"Ital J Dermatol Venerol"},{"issue":"1","key":"1950_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jid.2023.06.194","volume":"144","author":"JE Kim","year":"2024","unstructured":"Kim JE, Lee J, Huh YJ. Genomic profiling of the overlap phenotype between psoriasis and atopic dermatitis. J Invest Dermatol. 2024;144(1):43-52.e6. https:\/\/doi.org\/10.1016\/j.jid.2023.06.194.","journal-title":"J Invest Dermatol"},{"key":"1950_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1600-0560.2007.00782.x","volume":"35","author":"O ydin","year":"2008","unstructured":"ydin O, Engin B, O\u011fuz O, Ilvan S, Demirkesen C. Non-pustular palmoplantar psoriasis: is histologic differentiation from eczematous dermatitis possible? J Cutan Pathol. 2008;35:169\u201373.","journal-title":"J Cutan Pathol"},{"key":"1950_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/DAD.000000000000130","volume":"41","author":"L Penn","year":"2019","unstructured":"Penn L, Brinster NK. Eosinophils among the histological features of psoriasis. Am J Dermatopathol. 2019;41:347\u20139. https:\/\/doi.org\/10.1097\/DAD.000000000000130.","journal-title":"Am J Dermatopathol"},{"key":"1950_CR23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/exd.13077","volume":"25","author":"N Garzorz-Stark","year":"2016","unstructured":"Garzorz-Stark N, Krause L, Lauffer F, Atenhan A, Thomas J, Stark SP. A novel molecular disease classifier for psoriasis and eczema. Exp Dermatol. 2016;25:767\u201374. https:\/\/doi.org\/10.1111\/exd.13077.","journal-title":"Exp Dermatol"},{"key":"1950_CR24","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jid.2023.02.015","volume":"143","author":"F Fischer","year":"2023","unstructured":"Fischer F, Doll A, Uereyener D, Roenneberg S, Hillig C, Weber L. Gene expression-based molecular test as diagnostic aid for the differential diagnosis of psoriasis and eczema in formalin-fixed and paraffin-embedded tissue, microbiopsies, and tape strips. J Invest Dermatol. 2023;143:1461-1469.e5. https:\/\/doi.org\/10.1016\/j.jid.2023.02.015.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1950_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.29","volume":"1","author":"A Cunliffe","year":"2021","unstructured":"Cunliffe A, Gran S, Ali U. Can atopic eczema and psoriasis coexist? A systematic review and meta-analysis. Skin Health Dis. 2021;1(2):e29. https:\/\/doi.org\/10.1002\/ski2.29.","journal-title":"Skin Health Dis"},{"issue":"2","key":"1950_CR26","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/jdv.15213","volume":"33","author":"TA Kouwenhoven","year":"2019","unstructured":"Kouwenhoven TA, Bronckers IMGJ, van de Kerkhof PCM, Kamsteeg M, Seyger MMB. Psoriasis dermatitis: an overlap condition of psoriasis and atopic dermatitis in children. J Eur Acad Dermatol Venereol. 2019;33(2):e74\u20136. https:\/\/doi.org\/10.1111\/jdv.15213.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1950_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3329\/BSMMUJ.V10I2.32710","volume":"10","author":"M Bhuiyan","year":"2017","unstructured":"Bhuiyan M, Zakaria A, Sultana A, Haque A, Shawkat S. Clinico-epidemiological study of childhood psoriasis. Bangabandhu Sheikh Mujib Med Univ J. 2017;10:119\u201322. https:\/\/doi.org\/10.3329\/BSMMUJ.V10I2.32710.","journal-title":"Bangabandhu Sheikh Mujib Med Univ J"},{"key":"1950_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1046\/j.1525-1470.2001.018003188.x","volume":"18","author":"A Morris","year":"2001","unstructured":"Morris A, Rogers M, Fischer G, Williams K. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol. 2001;18:188\u201398. https:\/\/doi.org\/10.1046\/j.1525-1470.2001.018003188.x.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"1950_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/ijd.ijd_871_22","volume":"68","author":"Y Li","year":"2023","unstructured":"Li Y, Liu H, Zhang F. Biologics-induced immunophenotypic cross-switching in patients with psoriasis and atopic dermatitis. Indian J Dermatol. 2023;68(2):186\u201391. https:\/\/doi.org\/10.4103\/ijd.ijd_871_22.","journal-title":"Indian J Dermatol"},{"issue":"1","key":"1950_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jamadermatol.2023.4846","volume":"160","author":"A Al-Janabi","year":"2024","unstructured":"Al-Janabi A, Alabas O, Yiu Z. Risk of paradoxical eczema in patients receiving biologics for psoriasis. JAMA Dermatol. 2024;160(1):71\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2023.4846.","journal-title":"JAMA Dermatol"},{"key":"1950_CR31","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1111\/jdv.19394","volume":"37","author":"X Tang","year":"2023","unstructured":"Tang X, Li Q, Zhou Y, Zheng X, Zhou C, Hu Y. Predictive factors of atopic-like dermatitis induced by IL-17A inhibitors in patients with psoriasis: a 2-year follow-up study. J Eur Acad Dermatol Venereol. 2023;37:2509\u201316.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1950_CR32","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1093\/ced\/llaf271","volume":"50","author":"G Caldarola","year":"2025","unstructured":"Caldarola G, De Luca E, Amato S, et al. Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy. Clin Exp Dermatol. 2025;50(11):2185\u201391. https:\/\/doi.org\/10.1093\/ced\/llaf271.","journal-title":"Clin Exp Dermatol"},{"key":"1950_CR33","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1159\/000530608","volume":"239","author":"Z Su","year":"2023","unstructured":"Su Z, Zeng YP. Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review. Dermatology (Basel). 2023;239:646\u201357. https:\/\/doi.org\/10.1159\/000530608.","journal-title":"Dermatology (Basel)"},{"key":"1950_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13142","volume":"32","author":"M Napolitano","year":"2019","unstructured":"Napolitano M, Scalvenzi M, Fabbrocini G, Cinelli E, Patruno C. Occurrence of psoriasiform eruptions during dupilumab therapy for adult atopic dermatitis: a case series. Dermatol Ther. 2019;32:e13142. https:\/\/doi.org\/10.1111\/dth.13142.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1950_CR35","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jaci.2023.07.011","volume":"152","author":"A Al-Janabi","year":"2023","unstructured":"Al-Janabi A, Martin P, Khan AR, et al. Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics. J Allergy Clin Immunol. 2023;152(5):1237\u201346. https:\/\/doi.org\/10.1016\/j.jaci.2023.07.011.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1950_CR36","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/ijd.17742","volume":"64","author":"JT Tang","year":"2025","unstructured":"Tang JT, Xu MY, Wu NH, Wu F, Liu YQ. Rapid clinical improvement with tyrosine kinase 2 inhibitor deucravacitinib in overlapping psoriasis and atopic dermatitis. Int J Dermatol. 2025;64(7):1270\u20133. https:\/\/doi.org\/10.1111\/ijd.17742.","journal-title":"Int J Dermatol"},{"issue":"10","key":"1950_CR37","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/ced\/llae162","volume":"49","author":"M Napolitano","year":"2024","unstructured":"Napolitano M, Foggia L, Patruno C. Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis. Clin Exp Dermatol. 2024;49(10):1232\u20134. https:\/\/doi.org\/10.1093\/ced\/llae162.","journal-title":"Clin Exp Dermatol"},{"key":"1950_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2183729","volume":"34","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Pavia G, Avagliano J, Cortese A, Costanzo A. Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series. J Dermatolog Treat. 2023;34:2183729. https:\/\/doi.org\/10.1080\/09546634.2023.2183729.","journal-title":"J Dermatolog Treat"},{"key":"1950_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jaad.2024.03.007","volume":"91","author":"MG Hren","year":"2024","unstructured":"Hren MG, Guenin S, Khattri S. Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease. J Am Acad Dermatol. 2024;91:138\u201340. https:\/\/doi.org\/10.1016\/j.jaad.2024.03.007.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1950_CR40","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.12788\/cutis.0858","volume":"112","author":"MA Kaszycki","year":"2023","unstructured":"Kaszycki MA, Pixley JN, Feldman SR. Concurrent atopic dermatitis and psoriasis successfully treated with dual biologic therapy. Cutis. 2023;112(3):E13\u20136. https:\/\/doi.org\/10.12788\/cutis.0858.","journal-title":"Cutis"},{"key":"1950_CR41","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000235582","volume":"219","author":"A Esmailzadeh","year":"2009","unstructured":"Esmailzadeh A, Yousefifi P, Farhi D, Bachmeyer C, Cosnes J, Berenbaum F. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology. 2009;219:263\u20137. https:\/\/doi.org\/10.1159\/000235582.","journal-title":"Dermatology"},{"key":"1950_CR42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/09546634.2016.1230173","volume":"28","author":"M Nakamura","year":"2017","unstructured":"Nakamura M, Lee K, Singh R, Zhu TH, Farahnik B, Abrouk M. Eczema as an adverse effect of anti-TNF\u03b1 therapy in psoriasis and other Th1-mediated diseases: a review. J Dermatolog Treat. 2017;28:237\u201341. https:\/\/doi.org\/10.1080\/09546634.2016.1230173.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1950_CR43","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjd.20527","volume":"185","author":"PM Brunner","year":"2021","unstructured":"Brunner PM, Conrad C, Vender R. Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab. Br J Dermatol. 2021;185(4):865\u20137. https:\/\/doi.org\/10.1111\/bjd.20527.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1950_CR44","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1111\/jdv.19561","volume":"37","author":"S Eyerich","year":"2023","unstructured":"Eyerich S, Eyerich K. Iatrogenic switch from psoriasis to eczema: what does it mean and is it predictable? J Eur Acad Dermatol Venereol. 2023;37(12):2401\u20132. https:\/\/doi.org\/10.1111\/jdv.19561.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1950_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030796","volume":"14","author":"MB de Felici Del Giudice","year":"2025","unstructured":"de Felici Del Giudice MB, Ravaglia G, Brusasco M, Satolli F. Managing the overlap: therapeutic approaches in patients with concomitant psoriasis and atopic dermatitis-a case series. J Clin Med. 2025;14(3):796. https:\/\/doi.org\/10.3390\/jcm14030796.","journal-title":"J Clin Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01950-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01950-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01950-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:06:55Z","timestamp":1791950815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01950-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":45,"alternative-id":["1950"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01950-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"18 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Giacomo Caldarola has received consulting fees, honoraria and support for attending meetings from AbbVie, Lilly, Janssen, UCB, Novartis and LEO Pharma; Anna Campanati received payment\/honoraria for attending advisory board, scientific meeting and consultation from AbbVie, Almirall, Amgen, Eli Lilly, Novartis, LEO Pharma, Janssen, Bristol Myers Squibb, Janssen, Pfizer, Sanofi, Regeneron, UCB; Anna Campanati is an Editorial Board member of\n                      Dermatology and Therapy.\n                      Anna Campanati was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions; Marco Galluzzo has acted as speaker and\/or consultant for AbbVie, Almirall, Galderma, Eli Lilly, Johnson & Johnson, LEO Pharma, Novartis and Sanofi; Niccol\u00f2 Gori served as advisory board member for lectures for AbbVie, Sanofi, LEO Pharma, Galderma, Almirall, Novartis and Lilly. Maddalena Napolitano reports consulting fees from AbbVie, Lilly, LEO Pharma, Almirall, Sanofi, Pfizer; payment\/honoraria from AbbVie, Lilly, LEO Pharma, Almirall, Sanofi and participation on Data Safety Monitoring Board\/Advisory Board from Lilly, Sanofi, LEO Pharma, AbbVie and Almirall and support for attending meetings\/travel from Lilly, Sanofi, AbbVie, Almirall; Maddalena Napolitano is an Editorial Board member of\n                      Dermatology and Therapy.\n                      Maddalena Napolitano was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions; Matteo Megna acted as a speaker or consultant for AbbVie, Amgen, Eli Lilly, Novartis, LEO Pharma, Janssen, Almirall, Bristol Myers Squibb, UCB. Eleonora De Luca and Giulia Rech have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The process did not involve human or patient data and therefore did not require ethics committee approval.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}